Sodium iodohippurate (123I) is an inorganic compound and a radioactive tracer used in medical imaging. It is used primarily in renal imaging and cardiac imaging, as it is taken up by the kidneys and excreted in the urine. It is a salt of the iodide ion and hippuric acid, a molecule composed of carbon, hydrogen and nitrogen. In renal imaging, 123I is injected into the bloodstream and excreted by the kidneys. It is then detected by a gamma camera and the images are used to assess kidney function. In cardiac imaging, 123I is injected into the bloodstream and taken up by the heart muscle. It is then detected by a gamma camera and used to assess the function and structure of the heart. Overall, sodium iodohippurate (123I) is a safe and effective imaging tool for diagnosing and monitoring a variety of diseases and conditions. It has a short half-life of about 13 hours and does not accumulate in the body, making it a very safe tracer for medical imaging.
Sodium iodohippurate (123I), also known as iodohippurate sodium I-123 or ortho-iodohippurate (OIH), is a radiopharmaceutical medication used in nuclear medicine for diagnostic purposes. Here's a breakdown of its key features:
Main Function:
- Renal Imaging and Function Assessment: Sodium iodohippurate (123I) is primarily used to evaluate kidney function and blood flow through the kidneys. The kidneys play a vital role in filtering waste products from the blood. This radiopharmaceutical helps visualize the kidneys and assess their function by following how quickly it's taken up by the kidneys and excreted through the urine.
Applications:
- Diagnosis of Kidney Disease: Sodium iodohippurate (123I) can help diagnose various kidney problems, including blockages, reduced blood flow, or impaired filtration function.
- Evaluation of Kidney Transplants: It can be used to assess the function of a transplanted kidney after surgery.
Advantages:
- Targeted Imaging: Sodium iodohippurate (123I) is specifically taken up by the kidneys, allowing for clear images and functional assessment.
- Shorter Half-Life (13 hours): Compared to some other radiopharmaceuticals, its relatively short half-life minimizes radiation exposure to the patient.
Administration:
Sodium iodohippurate (123I) is typically injected intravenously (into a vein) for the imaging procedure.
Important Considerations:
- Radioactive Material: While the radiation exposure is lower than some isotopes, it's still important to be aware of the radioactive nature of sodium iodohippurate (123I). Pregnant and breastfeeding women will likely not be recommended this test due to potential risks to the baby.
- Allergic Reactions: As with any medication, allergic reactions are possible, though rare.
- Alternatives: Depending on the specific situation, other imaging tests like ultrasound or blood tests might be used instead of or alongside sodium iodohippurate (123I).